Teva-Xenon painkiller wins orphan designation from FDA

04/24/2013 | Pharmaceutical Business Review Online

The FDA has granted orphan-drug status to Teva Pharmaceutical and Xenon Pharmaceuticals' XEN402, an experimental drug for pain associated with erythromelalgia. A midstage trial showed that the drug, which inhibits the SCN9A sodium channel, alleviates erythromelalgia-related pain.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care